Associated Papers
Current opinions on Noonan syndrome and RASopathies.
Weaver KN et al.
Current Opinion in Pediatrics, 2026
Evolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections.
Gulrajani NB et al.
Prenatal Diagnosis, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.
Pattalachinti VK et al.
Npj Precision Oncology, 2025
Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold.
Wan X et al.
Theranostics, 2025
VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance.
Ohno S et al.
Computational and Structural Biotechnology Journal, 2025
Genetic aetiologies in relation to response to the ketogenic diet in 226 children with epilepsy.
Dahlin M et al.
Brain Communications, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.
Evrard YA et al.
Frontiers in Oncology, 2025
Cardiofaciocutaneous syndrome and immunodeficiency: data from an international multicenter cohort.
Di Majo BE et al.
Frontiers in Immunology, 2025
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.
Ozkaya N et al.
Blood Advances, 2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Martini DJ et al.
Cancer, 2024
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.
Özgü E et al.
Bjc Reports, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Chaudhary HA et al.
Drugs in R&d, 2024
Mutational Landscapes of Normal Skin and Their Potential Implications in the Development of Skin Cancer: A Comprehensive Narrative Review.
Riew TR et al.
Journal of Clinical Medicine, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.
Gazzin A et al.
Life (basel, Switzerland), 2024
Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease.
Dregoesc MI et al.
Iscience, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti-seizure medication.
Kenney-Jung DL et al.
American Journal of Medical Genetics. Part A, 2024
Status epilepticus in BRAF-related cardio-facio-cutaneous syndrome: Focus on neuroimaging clues to physiopathology.
Musto E et al.
Epilepsia Open, 2024
Identification of an unusual combination of actionable mutations through genomic profiling in a child with an aggressive sarcoma.
Sherif S et al.
Pediatric Blood & Cancer, 2024
Exploring the clinical complexity of cardio-facio-cutaneous syndrome: insights from a pediatric case series.
Ou Y et al.
Frontiers in Pediatrics, 2024
Non-canonical BRAF variants and rearrangements in hairy cell leukemia.
Langabeer SE
Oncology Research, 2024
Diagnostic efficiency of exome-based sequencing in pediatric patients with epilepsy.
Zou H et al.
Frontiers in Genetics, 2024
BRAF mutations and concurrent alterations in patients with soft tissue sarcoma.
Kobayashi H et al.
Genes, Chromosomes & Cancer, 2023
Systematic ophthalmologic evaluation in cardio-facio-cutaneous syndrome: A genotype-endophenotype correlation.
Crincoli E et al.
American Journal of Medical Genetics. Part A, 2023
Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy.
D'Onofrio G et al.
Pediatric Neurology, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Chehrazi-Raffle A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Hairy cell leukaemia with unusual BRAF mutations.
Maitre E et al.
Journal of Cellular and Molecular Medicine, 2023
BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.
Lauinger M et al.
Science Advances, 2023
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Molecular profiling of colorectal cancer in a genetically admixed Hispanic population.
Montes-Rodríguez IM et al.
Cancer Medicine, 2023
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
BRAF mutation in neuroblastoma: A rare finding.
Hutchins SC et al.
Pediatric Blood & Cancer, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Infantile epileptic spasms syndrome in children with cardiofaciocutanous syndrome: Clinical presentation and associations with genotype.
Kenney-Jung DL et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 2022
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S et al.
Acta Medica Academica, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa JM et al.
Cancers, 2022